BCM
AARD

Bridgeway Capital Management’s Aardvark Therapeutics AARD Stock Holding History

Bridgeway Capital Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$102K Hold
27,000
– – ﹤0.01% 1122
2025
Q4 		$354K Buy
27,000
+5,000
+23% +$62.4K 0.01% 891
2025
Q3 		$292K Buy
+22,000
New +$248K 0.01% 932

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bridgeway Capital Management's AARD Position: Q1 2026 in Review

Bridgeway Capital Management held its Aardvark Therapeutics (AARD) position steady in Q1 2026 at 27,000 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #1122.

Bridgeway Capital Management first reported a position in AARD in Q3 2025 and has held it in 3 quarters since. The position peaked at $354K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Bridgeway Capital Management held 27,000 shares of Aardvark Therapeutics worth $102K as of Q1 2026.
  • Bridgeway Capital Management left its Aardvark Therapeutics share count unchanged in Q1 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1122 holding.
  • Bridgeway Capital Management first reported a position in Aardvark Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Bridgeway Capital Management's Aardvark Therapeutics position peaked at $354K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.